Phasor Health, LLC
$3.2M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BeiGene AUS Pty Ltd
BeiGene AUS Pty Ltd reported $3,238,961.12 across General Payments, Research, and Ownership to 0 physicians and teaching hospitals across 825 transactions.
- $3.2M Top quartile payer
- All-tracks total
- 825 Above-median volume
- Transactions
- 0 —
- Recipients
- #347
- of 1,925 companies
BeiGene AUS Pty Ltd reported $3,238,961.12 across all CMS Open Payments tracks (General + Research + Ownership) to 0 physicians and teaching hospitals in Program Year 2024 - ranking #347 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total), averaging $0.00 per recipient.
BeiGene AUS Pty Ltd's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
28/100
Total payments
F
40/100
Transaction volume
F
16/100
Physician reach and Payment type diversity not applicable for BeiGene AUS Pty Ltd - no recorded activity on that dimension; its weight was redistributed to the applicable dimensions above.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer beigene-aus-pty-ltd BeiGene AUS Pty Ltd
$3.2M · #347/1,925 · 0.0% industry · PY2024
- TOT $3.2M
- RANK #347
- SHARE 0.0%
- TXN 825
- RCP 0
- CAT 0
- GEN n/a
- PY 2024
Volume peers
Nearest volume peer: Phasor Health, LLC ($3.2M)
BeiGene AUS Pty Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for BeiGene AUS Pty Ltd
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For BeiGene AUS Pty Ltd that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 0-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). Payments are distributed across multiple categories without a dominant single type.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BeiGene AUS Pty Ltd.
Showing 6 of 1,924 companies with CMS-reported payment data.
Endo USA, Inc.
$3.2M 10,750 recipients
Compare payment profiles
Chugai Pharmaceutical Co., Ltd.
$3.2M 133 recipients
Compare payment profiles
Viseon, Inc.
$3.2M 67 recipients
Compare payment profiles
BioLineRx USA, Inc.
$3.3M 137 recipients
Compare payment profiles
Kowa Holdings America, Inc.
$3.3M 0 recipients
Compare payment profiles
Put this to use
BeiGene AUS Pty Ltd ranks #347 of 1,925 by all-tracks total payments.
- See where BeiGene AUS Pty Ltd sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare payment categories across every manufacturer. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.